AstraZeneca breached deal on paediatric budesonide, Verus claims
This article was originally published in Scrip
Executive Summary
The US speciality pharma company Verus Pharmaceuticals is suing AstraZeneca and its wholly owned subsidiary Tika for $1.3 billion on claims that the defendants "blatantly disregarded" their contractual obligations to Verus under three R&D agreements from 2007 relating to paediatric asthma.